[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
April 1994

The Mystery of Antiphospholipid Antibodies in Sneddon's Syndrome-Reply

Author Affiliations

Department of Dermatology University of Innsbruck Anichstasse 35 A-6020 Innsbruck, Austria

Innsbruck, Austria

Arch Dermatol. 1994;130(4):520. doi:10.1001/archderm.1994.01690040128025

The discrepancy of antiphospholipid antibody (aPL) findings in Sneddon's syndrome (SS) is indeed striking. We are, therefore, grateful to Drs Piette and Frances for their questions and comments, the answers to which will, hopefully, clarify part of the mystery surrounding aPL in SS: (1) The presence or absence of aPL was not an exclusion or an inclusion criterion for our study1 (see the case definition on page 437 of our article, which appeared in the April 1993 issue of the Archives). At the end of this study, in the spring of 1991, none of the patients tested positive for aPL; yet, following the same inclusion criteria, we have since studied 11 patients with SS, one of them positive for aPL (310 mU/mL). (2) The cut-off value for the determination of anticardiolipin antibodies was less than 15 mU/mL (Quanta light ACA). (3) Approximately 10% of patients with systemic lupus who

First Page Preview View Large
First page PDF preview
First page PDF preview